ClinicalTrials.gg
CompletedNCT07284056Updated Nov 17, 2026

Prevention and Treatment of Early Postoperative Atelectasis Using The MetaNeb System in Patients Underwent Esophagectomy

An interventional study of MetaNeb Therapy and Standard of care in Atelectases, Postoperative Pulmonary, sponsored by Shanghai Zhongshan Hospital. Completed at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Pulmonary Atelectasis with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Pulmonary Atelectasis · China.

Enrollment
4th of 21
178 · median 90
Started
2026
with 4 others
No phase
19 of 24
12 open now
Registered
19th of 24
by date
Lead sponsor
4 of 24
Shanghai Zhongshan Hospital

Among the 24 studies in Pulmonary Atelectasis with a site in China, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2026, is one of 19 with no phase, and was the 19th registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

13 of the 24 studies in Pulmonary Atelectasis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pulmonary Atelectasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether the MetaNeb® System can effectively prevent and treat early postoperative atelectasis in adult patients admitted to ICU after esophagectomy for esophageal cancer.

The main question it aims to answer is: can the MetaNeb® system significantly reduce the lung ultrasound score (LUSS) indicating atelectasis on postoperative days 1 and 2? Participants will be randomly assigned to either the standard treatment or MetaNeb group, undergo lung ultrasound and electrical impedance tomography (EIT) assessments on postoperative days 1 and 2, receive at least 4 sessions of MetaNeb therapy on postoperative day 1 if in the intervention group, be monitored for oxygenation indices, ICU stay duration, incidence of mechanical ventilation, need for bronchoscopic intervention, and adverse events like pneumothorax.

03

Conditions studied

  • Atelectases, Postoperative Pulmonary

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 85 years.
  2. Patients who are scheduled for ICU admission after esophagectomy for esophageal cancer.

Exclusion criteria

Exclusion Criteria:

  1. Presence of an artificial airway at the time of ICU admission.
  2. Planned ICU stay less than 24 hours.
  3. Patients with to the use of the MetaNeb® System, or those unable to cooperate due to organic or psychiatric conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Sham comparator
    Standard Group

    Behavioral: Standard of care

  • Experimental
    MetaNeb Group

    Device: MetaNeb Therapy

Interventions

  • DeviceMetaNeb Therapy

    Patients in the MetaNeb group receive at least 4 sessions of MetaNeb therapy on postoperative day 1 (each session includes cycles of CPEP and CHFO modes totaling 10 minutes).

  • BehavioralStandard of care

    Standard postoperative care, including guidance on coughing and expectoration, turning and back percussion, and early mobilization (getting out of bed for physical activity).

06

What researchers measure

Primary outcomes

  1. The difference of lung ultrasound scores (LUSS) indicating atelectasis on postoperative day 1 and 2

    Time frame: From postoperative day 1 to day 2

Secondary outcomes

  1. The difference of dorsal ventilation region assessed by electrical impedance tomography (EIT) on postoperative day 1 and 2

    Time frame: From postoperative day 1 to day 2

  2. The difference of PaO2/FiO2 ratios on postoperative day 1 and 2

    Time frame: From postoperative day 1 to day 2

  3. The number of cases that underwent bronchoscopy intervention during ICU stay

    Time frame: From admission to ICU discharge

  4. The number of cases that underwent high flow oxygen therapy or mechanical ventilation

    Time frame: From admission to ICU discharge

  5. Length of ICU stay

    Time frame: From admission to ICU discharge

  6. The number of cases that develop pneumothorax during intervention

    Time frame: From admission to the end of intervention at postoperative day 2

  7. Clinical Pulmonary Infection Score

    Clinical Pulmonary Infection Score

    Time frame: From postoperative day 1 to day 2

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided — It might compromise the interests of MetNeb company and we still need to negotiate it further.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Apr 2026, 3 months.

Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's 3 months is below that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → May 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 16, 2025
StartActual
Jan 5, 2026
Primary completionActual
Apr 29, 2026
CompletionActual
May 31, 2026was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 17, 2026
Sites
1 site added
Show site
  • Zhongshan hospital · Shanghai, China
Nov 17, 2026
Start date
Jan 1, 2026→Jan 5, 2026 (actual)
Nov 17, 2026
Primary completion
Apr 30, 2026→Apr 29, 2026 (actual)
Nov 17, 2026
Study completion
Dec 31, 2026→May 31, 2026 (actual)
Nov 17, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedClinical Pulmonary Infection ScoreTime frame: From postoperative day 1 to day 2
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Completed
    1 site added
    Show site
    • Zhongshan hospital · Shanghai, China
    Start date Jan 1, 2026→Jan 5, 2026 (now actual)
    Primary completion Apr 30, 2026→Apr 29, 2026 (now actual)
    Study completion Dec 31, 2026→May 31, 2026 (now actual)
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedClinical Pulmonary Infection ScoreTime frame: From postoperative day 1 to day 2
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284056
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jan 5, 2026
Primary completion
Apr 29, 2026
Completion
May 31, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion